Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is second most common target of SARS-CoV-2, which leads to complications, including myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well other major thrombotic events because direct endothelial injury an excessive systemic inflammatory response. This review focuses on similarities differences pathways involved in COVID-19 atherosclerosis. Anti-inflammatory agents immunomodulators have recently assessed, may constitute rational treatments for reduction both atherosclerotic heart disease.